Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB) A Systematic Review and Delphi Consensus Statement


Pijnappel, Esther N, Suurmeijer, J Annelie, Koerkamp, Bas Groot, Kos, Milan, Siveke, Jens T, Salvia, Roberto, Ghaneh, Paula, van Eijck, Casper HJ, van Etten-Jamaludin, Faridi S, Abrams, Ross et al (show 14 more authors) (2023) Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB) A Systematic Review and Delphi Consensus Statement. JAMA ONCOLOGY, 8 (6). pp. 929-937.

[img] Text
ONC21-1894_Merged_PDF.pdf - Author Accepted Manuscript
Access to this file is embargoed until Unspecified.
Download (1MB)

Abstract

<h4>Importance</h4>Pancreatic cancer is the third most common cause of cancer death; however, randomized clinical trials (RCTs) of survival in patients with resectable pancreatic cancer lack mandatory measures for reporting baseline and prognostic factors, which hampers comparisons between outcome measures.<h4>Objective</h4>To develop a consensus on baseline and prognostic factors to be used as mandatory measurements in RCTs of resectable and borderline resectable pancreatic cancer.<h4>Evidence review</h4>We performed a systematic literature search of the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, and Embase for RCTs on resectable and borderline resectable pancreatic cancer with overall survival as the primary outcome. We produced a systematic summary of all baseline and prognostic factors identified in the RCTs. A Delphi panel that included 13 experts was surveyed to reach a consensus on mandatory and recommended baseline and prognostic factors.<h4>Findings</h4>The 42 RCTs that met inclusion criteria reported a total of 60 baseline and 19 prognostic factors. After 2 Delphi rounds, agreement was reached on 50 mandatory baseline and 20 mandatory prognostic factors for future RCTs, with a distinction between studies of neoadjuvant vs adjuvant treatment.<h4>Conclusion and relevance</h4>This findings of this systematic review and international expert consensus have produced this Consensus Statement on Mandatory Measurements in Pancreatic Cancer Trials for Resectable and Borderline Resectable Disease (COMM-PACT-RB). The baseline and prognostic factors comprising the mandatory measures will facilitate better comparison across RCTs and eventually will enable improved clinical practice among patients with resectable and borderline resectable pancreatic cancer.

Item Type: Article
Uncontrolled Keywords: Humans, Pancreatic Neoplasms, Neoadjuvant Therapy, Delphi Technique
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 26 Jun 2023 07:46
Last Modified: 17 Mar 2024 13:58
DOI: 10.1001/jamaoncol.2022.0168
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3155153
Dimensions
Altmetric
CORE (COnnecting REpositories)